My rough figures indicate EPS for FY14 could be in the range of $0.03 (17m annualised NPAT / 563m shares on issue).
This would be in line with forecasts I think and would put it on a p/e of approx. 24x.
I think it's fairly priced but with a good growth profile.
Ann: Mayne Pharma results and product update , page-2
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.73 |
Change
0.140(3.05%) |
Mkt cap ! $402.4M | |||
| Open | High | Low | Value | Volume |
| $4.59 | $4.73 | $4.54 | $464.8K | 99.77K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 111 | $4.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.73 | 9143 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |